<unk>  is used to treat lower respiratory tract, skin, urinary tract, blood-stream, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the person.<unk>  is also commonly prescribed off-label for nebulization in people with cystic fibrosis for the suppression of Pseudomonas aeruginosa in the lungs as well as the treatment of pulmonary exacerbations. Those with kidney disease are dosed less frequently.<unk>  is the first-line treatment for the tropical infection, melioidosis, an important cause of sepsis in Asia and Australia. Labeled indications include the treatment of patients with: * Pseudomonas aeruginosa infections * other Gram-negative, aerobic infections * neutropenic fever As a class, cephalosporins have activity against Gram-positive and Gram-negative bacteria. The balance of activity tips toward Gram-positive organisms for earlier generations; later generations of cephalosporins have more Gram-negative coverage.<unk>  is one of the few in this class with activity against Pseudomonas aeruginosa. It is not active against methicillin-resistant Staphylococcus aureus. Spectrum of activity Clinically relevant organisms against which<unk>  has activity include: *Gram-negative aerobes such as Enterobacter, Escherichia coli, Haemophilus influenzae, Klebsiella spp., Proteus spp., Pseudomonas aeruginosa, and Neisseria meningitidis *Gram-positive aerobes, such as group B streptococci, Streptococcus pneumoniae, and Streptococcus pyogenes<unk>  generally has poor efficacy against anaerobes, such as Bacteroides spp. The following represents MIC susceptibility data for a few clinically significant pathogens: * Escherichia coli – 0.015 μg/mL – 512 μg/mL * Pseudomonas aeruginosa – ≤0.03 μg/mL – 1024 μg/mL
Ceftazidime
Meropenem
Aztreonam
Imipenem
Vancomycin
Resistin
Ertapenem
Cefotaxime